MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
6.37
-0.32
-4.78%
After Hours: 6.52 +0.15 +2.35% 19:34 04/12 EDT
OPEN
6.65
PREV CLOSE
6.69
HIGH
6.70
LOW
6.25
VOLUME
1.41M
TURNOVER
0
52 WEEK HIGH
22.75
52 WEEK LOW
5.25
MARKET CAP
484.81M
P/E (TTM)
-4.2467
1D
5D
1M
3M
1Y
5Y
What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences
Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion. Vertex is gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. The acquisition also includes Alpine's protein engineering and autoimmune expertise. The deal brings no revenues until at least 2027 and will produce modest upside for Vertex.
Seeking Alpha · 1d ago
Weekly Report: what happened at TVTX last week (0401-0405)?
Weekly Report · 4d ago
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere Therapeutics, Inc. Will present eight posters in classical homocystinuria (HCU) at two major conferences in 2024. The Company will present at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International in North Carolina.
Barchart · 04/04 15:30
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Travere Therapeutics, Inc. Will present nine abstracts in rare kidney disease at the World Congress of Nephrology in Buenos Aires, Argentina, in 2024. The Company will also present abstracts at the American Nephrology Nurses Association in Orlando, Florida.
Barchart · 04/03 15:30
Weekly Report: what happened at TVTX last week (0325-0329)?
Weekly Report · 04/01 12:10
Travere Therapeutics Cut to Neutral From Buy by Guggenheim
Dow Jones · 03/27 10:58
Guggenheim Downgrades Travere Therapeutics to Neutral
Benzinga · 03/27 10:49
Weekly Report: what happened at TVTX last week (0318-0322)?
Weekly Report · 03/25 12:14
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.